{"title":"[Enhancing CAR-T/CAR-NK Cells through by Cytokine Signaling].","authors":"Yuki Kagoya","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Chimeric antigen receptor(CAR)T-cell therapy has already been in the clinic due to its marked efficacy against several hematologic cancers. However, a significant number of patients relapse after a transient response, and the applicable diseases are still limited. Cytokine signaling is one of the most promising targets to enhance the therapeutic efficacy of CAR-T cells. At the same time, several cytokines are closely associated with toxicity, as exemplified by cytokine release syndrome. Here I will present representative findings on cytokines that have been shown to modulate CAR-T cell functions. I will also present our recent studies on how to simultaneously address efficacy and safety issues in CAR-T cell therapy. We will also briefly discuss CAR-NK cells, in which cytokines play an essential role.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"304-309"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Chimeric antigen receptor(CAR)T-cell therapy has already been in the clinic due to its marked efficacy against several hematologic cancers. However, a significant number of patients relapse after a transient response, and the applicable diseases are still limited. Cytokine signaling is one of the most promising targets to enhance the therapeutic efficacy of CAR-T cells. At the same time, several cytokines are closely associated with toxicity, as exemplified by cytokine release syndrome. Here I will present representative findings on cytokines that have been shown to modulate CAR-T cell functions. I will also present our recent studies on how to simultaneously address efficacy and safety issues in CAR-T cell therapy. We will also briefly discuss CAR-NK cells, in which cytokines play an essential role.